Try our beta test site

Safety Study in Adolescent and Adult Patients With Asthma

This study has been completed.
Information provided by (Responsible Party):
Amphastar Pharmaceuticals, Inc. Identifier:
First received: November 15, 2011
Last updated: February 10, 2017
Last verified: February 2017
E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.

Condition Intervention Phase
Drug: Placebo
Drug: Primatene Mist
Drug: Epinephrine inhalation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A 3-month Safety Evaluation Extension to the 12-week E004-C Study in Asthma Patients (A Double Blinded, Placebo-controlled, Parallel, 3-month Safety Study in Adolescent and Adult Patients With Asthma)

Resource links provided by NLM:

Further study details as provided by Amphastar Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Adverse Events [ Time Frame: up to 12 weeks ]
    Recording of all adverse events experienced during the course of the study

Secondary Outcome Measures:
  • Change in 12 lead ECG including QT/QTc analysis [ Time Frame: Study visit 4, 8 and 12, greater than one hour after last dose ]
    A 12-lead ECG (routine and QT/QTc) will be measured and recorded, provided that dosing of study drug has been performed greater than 1 hour prior to conducting the measurements.

  • Asthma Exacerbations [ Time Frame: up to 12 weeks ]
    Review use of resuce inhaler for treatment of asthma exacrbations occuring between doses of study medication.

Enrollment: 208
Study Start Date: November 2011
Study Completion Date: July 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm T
Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals
Drug: Epinephrine inhalation
125 mcg/inhalation, 2 inhalations QID
Placebo Comparator: Arm P
Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals
Drug: Placebo
0 mcg/inhalation, 2 inhalations QID
Active Comparator: Arm A
Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals
Drug: Primatene Mist
220 mcg/inhalation, 2 inhalations QID


Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Only subjects who have successfully completed the E004-C study within the last 135 days or those who are actively enrolled in the current study E004-C at the time of the study extension initiation
  • Male and female asthma patients aged 12 - 75 years
  • Patients with documented asthma, requiring inhaled epinephrine or beta 2-agonist treatment
  • No significant changes in asthma therapy and no asthma-related hospitalization or emergency visits, within 4 weeks prior to Screening
  • Demonstrating satisfactory techniques in the use of metered-dose inhaler and a hand held peak expiratory flow meter
  • Female patients of child-bearing potential must be non-pregnant and non-lactating at Screening and throughout the study, and must use an acceptable method of contraception during the study

Exclusion Criteria:

  • A smoking history of 10-pack years, or having smoked within 12 months of screening
  • Any current or past medical conditions that, per investigator discretion, might significantly affect responses to the study drugs, other than asthma
  • Concurrent clinically significant diseases
  • Known intolerance or hypersensitivity to any component of the study drugs
  • Recent infection of the respiratory tract, before screening
  • Use of prohibited medications
  • Having been on other investigational drug/device studies in the last 30 days prior to screening
  • Known or highly suspected substance abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01476904

  Show 27 Study Locations
Sponsors and Collaborators
Amphastar Pharmaceuticals, Inc.
Study Director: Safety Monitor Amphastar Pharmaceuticals, Inc.
  More Information

Responsible Party: Amphastar Pharmaceuticals, Inc. Identifier: NCT01476904     History of Changes
Other Study ID Numbers: API-E004-CL-C2
Study First Received: November 15, 2011
Last Updated: February 10, 2017

Keywords provided by Amphastar Pharmaceuticals, Inc.:
Bronchial Asthma
Shortness of breath

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents processed this record on March 29, 2017